EPFL Alumni

With more than 35'000 graduates, spread over 80 countries, EPFL Alumni is an exclusive network of professionals working in research, management, industry and public service. All EPFL graduates have access to an invaluable community of people connected to EPFL that can provide career and project advice.

EPFL Alumni supports EPFL startups through its mentoring and investment programs. Geared towards early-stage ventures, those services are aimed at connecting promising entrepreneurs based on EPFL campus with industry mentors and business angels (alumni of EPFL or not) through customized workshops and networking events. To do so, EPFL Alumni has partnerships with major business angels clubs in Switzerland.

Interested in our startup programs? Send us an email at innovation.alumni@epfl.ch or check our website at https://www.epflalumni.ch/start-up/
Launched in 2005 with the initial support of Lombard Odier, Innogrants financed more than 100 teams and helped to create 65+ startups. These startups subsequently received more than CHF 300M in additional grants and equity. Innogrants are mostly in the form of an EPFL salary, with some business development additional options.
Venturelab – World-class Startups. Swiss made.

Together with successful founders, key academic and industry partners, Venturelab designs and operates programs to bring the best startup talents to the next level of development. Our mission is to support entrepreneurs towards successful fundraising and business growth throughout the evolution of their company. Venturelab has 19 years of experience bringing Switzerland’s best entrepreneurs to the heart of technology hotspots: Silicon Valley, New York, Boston, Barcelona, Beijing, Shanghai, Shenzhen, and Hong Kong. Companies founded by the 360 Venture Leaders alumni have created more than 3,500 jobs, and raised more than CHF 1.4 billion in capital.

We are also particularly proud of the success of our mandate to run the operations of the Venture Kick Foundation since its launch in 2007. So far, the program of financial support, training and network, has led to the creation of 454 companies and 6,033 jobs. Venture Kick alumni companies have attracted a total of CHF 2.5 billion, and represent 55 companies ranked at the TOP 100 Swiss Startup Award 2018.
Swisscom Ventures invests in promising tech companies that innovate in ICT Infrastructure & Cloud, Enterprise Solutions, applied A.I., Cybersecurity, Digital Health and Robotics. As a committed investor and established ICT company, we help entrepreneurs with comprehensive know-how, do-how and provide extensive strategic value besides financial means. Swisscom Ventures, together with institutional investors, founded the Digital Transformation Fund, which has a total capital of CHF 150 million and when combined with CHF 50m from the Swisscom balance sheet this represents a total investment program of CHF 200m. To find out more about Swisscom Ventures and our portfolio companies, visit our website http://ventures.swisscom.com
This event is sponsored by

INNOVAUD – The hub of innovation in Vaud
Innovaud is the first port of call for innovation in Vaud, providing free support to innovative start-ups, scale-ups and small and medium-sized businesses in the canton. Innovaud focuses on innovations in cutting-edge technology or new approaches, and prioritizes support for businesses in the fields of life sciences, precision industry, cleantech, and information and communication technology (ICT). This includes: financing, support, promotion, premises and networking. For more information, please contact:
www.innovaud.ch | Twitter: @innovaud | LinkedIn: Innovaud | Innovaud application available on the App Store, Google Play and Windows Phone.
Monthly newsletter --> www.innovaud.ch

Office for Economic Affairs and Innovation (SPEI)
The Office for Economic Affairs and Innovation (SPEI) supports companies that are located in the canton of Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs from their startup phase through the internationalisation of their business. It guides business people through local and regional governmental processes and puts them in touch with organisations that are appropriate to their specific needs: consulting, financing, technology support, etc. SPEI can also provide direct financial support to SMEs and start-ups in advanced technologies and industries.
For more information : www.vaud.ch/economy
CNNMoney Switzerland was launched on January 24, 2018. It produces three hours of content daily, news, market updates, and specialized shows on technology and culture. The more than 250 guests who have already appeared on the network include members of the Federal Council, foreign heads of state, CEOs of SMI-listed companies, and leaders of international organizations. CNNMoney Switzerland can be watched on television, as well as on www.cnnmoney.ch, Facebook, LinkedIn, Twitter, YouTube, Xing, and Instagram.
Program:

17h00: Doors open for startups exhibition
18h30: Welcome words
19h00: Keynote
Steve Anavi (MT’06), Co-founder & President, Qonto
«My Journey from Engineer to Entrepreneur»
19h15: Pitch competition
20h15: Keynote
Madiha Derouazi (PhD CGC’05), Founder & CEO, AMAL Therapeutics
«Biotech, alone and over 37 million raised: story of AMAL Therapeutics»
20h30: Final round with the four best startups
20h45: Closing words, buffet networking and startups exhibition
Keynote speakers:

“My Journey from Engineer to Entrepreneur”

Steve Anavi is the Co-founder and President of Qonto, the leading SME neobank in France, where he looks after technology, product, and operations. Prior to Qonto, he co-founded Smok.io (acquired by a Fortune 500), led operations at Groupon and worked at Deloitte Consulting. He holds a MSc in Microengineering from EPFL, and an MBA from INSEAD.
"Biotech, alone and over 37 million raised: story of AMAL Therapeutics”

Madiha Derouazi founded AMAL Therapeutics in 2012 as a spin-off from the University of Geneva, Switzerland. In the Laboratory of Tumour Immunology she designed and characterized the CPP-based multi-epitopic cancer vaccine that is currently being progressed by AMAL Therapeutics, and allowed her to raise over 37 million CHF.
PITCH COMPETITION
INDEX

Group 1
Smeetz p.12
HiLyte p.13
4D Lifetec p.14
SwissDeCode p.15
Tolremo Therapeutics p.16

Group 2
Blochlabs p.17
Medyria p.18
AgroSustain p.19
Pattern BioSciences p.20
Wake it p.21
Positrigo p.22

Group 3
Swiss Public IT p.23
Resistell p.24
Droople p.25
Scailyte p.26
Foodetective p.27
Synendos Therapeutics p.28

Group 4
Nanogence p.29
Juvabis p.30
MeduSoil p.31
Volumina Medical p.32
Tayo p.33
Smeetz is a SaaS booking platform that helps leisure, sport and event organizers increase their revenues. We bring one major technical innovation to the industry with a machine learning-based dynamic pricing model. We have successfully managed our market launch with more than 150 customers and signed partnerships with nationwide companies.

Smeetz is looking for a Series A of CHF 1’800’000 to 2’400’000.

www.smeetz.com
alexandre.martin@smeetz.com
+41 78 657 70 54
Briac Barthes  
Co-founder & CEO  

Sector:  
CleanTech  

We developed a consumable based iron battery that aims at eradicating kerosene lamps use in developing countries, and that can charge a phone.

HiLyte is looking for CHF 600’000.

www.hilyte-power.com  
briac.barthes@hilyte-power.com  
+41 77 402 57 13
4D Lifetec AG is a highly innovative Swiss startup developing the 4D Lifetest, an innovative, standardized, cost effective ultra-precise liquid biopsy assay for the detection of cancer which is currently under clinical validation.

4D Lifetec is looking for CHF 9’000’000.

www.4dlifetec.com
arne.faisst@4dlifetec.com
+41 79 434 10 49
SwissDeCode has the vision of building trust and securing the global food supply chain. Based near Lausanne, the company helps farmers and food manufacturers to grow and produce food that is safe to eat by delivering real time certification of authenticity, safety and quality of products, processes and premises.

SwissDeCode is looking for CHF 3’000’000.

www.swissdecode.com
gianpaolo.rando@swissdecode.com
+41 79 930 79 91
There is a high unmet need for durable therapeutic options for cancer patients. Although cancer drugs relieve patients from their tumor burden, they oftentimes lose their effectiveness over time. TOLREMO develops novel small molecules that eradicate drug resistant cancer cells right at the start of a therapy. TOLREMO’s resistance-breaking add-on therapies can be combined with existing cancer drugs, to meaningfully extend the lives of patients suffering from different types of cancer.

TOLREMO is looking for CHF 20’000’000.
Ian Rousseau
Co-founder & CEO

Sector:
Manufacturing, semi-conductors

Vacuum pressure measurement is a key technology for quality assurance in electronics manufacturing. Compared to the state-of-the-art, our vacuum gauge-on-a-chip promises lower cost, improved performance, and longer lifetime.

BlochLabs is looking for a CHF 600'000 seedround by the end of 2019.

www.bloch-labs.com
rousseau@bloch-labs.com
+41 21 510 23 07
Gilles Lachkar  
CEO  

Sector: Medtech

Medyria, in partnership with leading cardiovascular surgeons, has developed a unique proprietary technology platform: the TrackCath system. The TrackCath system, a patented sensing technology, measures blood flow velocity. Applied to a TrackCath access catheter, the sensing technology identifies small blood vessel orifices for cannulation purposes. The TrackCath system aims to replace X-ray and contrast media during minimally invasive cardiovascular procedures, for improved patient safety.

Medyria is looking for CHF 15'000'000.

www.medyria.com  
gilles.lachkar@medyria.com  
+41 76 823 87 52
AgroSustain develops and brings to market natural plant-inspired solutions to stop and prevent further development of molds on agronomically important crops. AgroSustain’s product extends shelf-life of crops infected with broadly spread molds.

AgroSustain is looking for CHF 3’000’000.
Pattern BioSciences uses gene circuit technology to design programmable gene therapies that can recognize complex molecular patterns, leading to higher efficacy, lower toxicity, and a reduced development attrition rate. We aim to occupy the early value chain in the rapidly growing gene therapy market both via internal and partnered projects.

Pattern BioSciences is looking for CHF 1’000’000.
At “Wake it” we help young people who want to wake up in a good mood by increasing their motivation and avoiding tediousness unlike other conventional and boring current alarms.

Wake it is looking for CHF 150’000 to 200’000.
Dementia is a major problem in our aging societies costing nearly a trillion USD worldwide per year. Treatments are on the horizon, but an affordable and widely available diagnostic technique is still missing. Positrigo’s brain imaging system, called CortEx, offers functional brain imaging to everyone at a fraction of today’s cost. Positrigo CortEx is up to ten times cheaper and up to ten times smaller than currently available multi-modal whole-body scanners. Such an affordable PET will be able to accommodate the expected large increase in PET examinations at a much better cost-to-benefit ratio than current systems. With CortEx, scanning centers with five or more scanners operating in parallel become possible.

Positrigo is looking for CHF 5’500’000.

www.positrigo.com
max.ahnen@positrigo.com
+41 77 422 76 79
Swiss Public IT is a Switzerland based high-tech company that reimagines the way telecommunication infrastructure, IT infrastructure, and value-added services are built and deployed. Its solutions allow infrastructure to be built at a lower cost to enable the adoption of new technologies such as distributed ledgers and Internet-of-Things at scale. Building on connectivity, Swiss PIT will transform the agriculture sector by introducing an e-agriculture platform based on blockchain and IoT connected devices.

Swiss Public IT is looking for CHF 5’200’000.

www.swiss-pit.com
Bertrand.Ndzana@swiss-pit.com
+41 79 514 48 55
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. Because the test is growth independent, we reduce the time taken to get a result from days to hours. Our customers, hospital labs, will buy it because we save patients' lives and cost.

Resistell is looking for CHF 4’000’000.
Droople provides utilities, businesses, communities and governing bodies with its full-stack solution to increase the efficiency of their water management processes by at least 20%.

Droople is looking for CHF 750’000.
Scailyte is a data science company in the emerging market of single-cell analysis (to reach USD 1Bn in the next 2 years). We develop and commercialize data analytics tools for extracting knowledge from single-cell data and we partner with industry and hospitals to discover novel biomarkers for precision medicine (multi-billion market).

Scailyte is looking for CHF 10’000’000.
Andrea Tassistro
Co-founder & CEO

Sector:
Foodtech & Saas

All in one operating system for the online F&B and hospitality industry.

Foodetective is looking for CHF 3’000’000 to 5’000’000.

www.foodetective.co/en/
andrea@foodetective.co
+41 78 657 12 11
First in class inhibitors that enable restoring normal brain functions providing a safe and effective therapy for neuropsychiatric disorders. Posttraumatic stress disorder as primary indication based on optimal scientific rationale, high unmet need and profitable market (25M patients in the US; estimated market of $1.2B). Drug candidate selected.

Synendos Therapeutics is looking for CHF 5’000’000.
At Nanogence we develop synthetic tailor-made novel synthetic material in a B2B framework for application fields such as construction, pharmaceutical and mobility. As our first go-to market we chose the application in construction sector. The products are synthesized materials placed at the beginning of the value chain that improves the characteristics of the materials, while being cheaper and eco-friendlier than any comparable products if available in the market.

Nanogence is looking for CHF 5'000'000.
Juvabis is a seed-stage biotech startup that develops next-generation antimicrobial therapeutics against highly drug resistant infections. Juvabis holds an exclusive world-wide license for a strong IP portfolio invented at the ETH and University of Zurich by its co-founders. Juvabis has benefited from generous non-dilutive support by the Innovative Medicines Initiative and developed a lead to IND-stage clinical candidate with Phase-1 trial scheduled to begin in May 2019. Juvabis seeks to close a seed round in 2019 and to enter into a clinical development partnership for phase 2 trials in 2020.

Juvabis is looking for CHF 2'000'000.

www.juvabis.com
sven.hobbie@juvabis.com
+41 76 558 59 21
MeduSoil delivers the world’s first bio-based carbon mineralization agents for ground stabilization solutions. The EPFL spin-off commercializes a liquid solution which reacts with the ground and stabilizes it to enable contractors build on solid foundations and protect infrastructures against major threats such as earthquakes, soil erosion and landslides. MeduSoil stores carbon in the subsurface in the form of mineral binders which improve ground strength by 30% and reduce current costs by 20% compared to the use of conventional, cement-based industrial fluids.

www.medusoil.com
dimitrios@medusoil.com
+41 79 174 12 47
Volumina Medical develops disruptive medical devices for the regeneration of soft tissues (breast, body, face) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes. It addresses the need of 800’000 patients/year needing to regain durably their physical and functional integrity, as well as the need of plastic and reconstructive surgeons missing a safe and efficient solution to repair the body in 3D.

Volumina Medical is looking for CHF 15’000’000.

www.volumina-medical.ch
amelie.beduer@volumina-medical.ch
+41 78 855 02 82
The #1 property management platform to share information, communicate efficiently and automate simple tasks.

Tayo is looking for CHF 1’000’000.

Gilles Martin
Chief Operating Officer

Sector:
Proptech

www.tayo.io
gilles.martin@tayo.io
+41 78 814 33 45
Your notes: